Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Carbidopa
Drug ID BADD_D00359
Description Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate. It potently inhibits aromatic amino acid decarboxylase (DDC) and due to its chemical properties, it does not cross the blood-brain barrier. Due to its activity, carbidopa is always administered concomitantly with [levodopa]. An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.[T394] The first approved product by the FDA containing only carbidopa was developed by Amerigens Pharmaceuticals Ltd and approved on 2014.[L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination therapy developed by Mayne Pharma in 1992.[L5113]
Indications and Usage For treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), post-encephalitic parkinsonism
Marketing Status Prescription
ATC Code Not Available
DrugBank ID DB00190
KEGG ID D00558
MeSH ID D002230
PubChem ID 34359
TTD Drug ID D0P7JZ
NDC Product Code 67628-2001; 43386-980; 70771-1355; 63415-0024; 38779-0202; 51407-314; 42799-123; 65977-0131; 70600-018; 12780-4420; 52423-0901; 0006-0007; 62331-014; 62991-2848; 25010-711; 16714-067; 63629-1932; 43975-220; 59651-146; 58624-0621; 49452-1692; 70710-1221; 40032-980; 51504-0001
Synonyms Carbidopa | Methyldopahydrazine | MK-486 | MK 486 | MK486 | Lodosin | Lodosyn | MK-485 | MK 485 | MK485 | Carbidopa, (S)-Isomer | Carbidopa, (R)-Isomer
Chemical Information
Molecular Formula C10H14N2O4
CAS Registry Number 28860-95-9
SMILES CC(CC1=CC(=C(C=C1)O)O)(C(=O)O)NN
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neuropathy peripheral17.09.03.003--Not Available
Nightmare19.02.03.003--Not Available
Oculogyric crisis06.05.02.002; 17.01.03.002--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Paranoia19.05.01.005--Not Available
Pemphigoid23.03.01.004; 10.04.02.002--Not Available
Pemphigus23.03.01.005; 10.04.02.003--Not Available
Phlebitis24.05.03.001; 12.02.01.002--
Pollakiuria20.02.02.007--
Priapism21.03.01.005--Not Available
Protein urine13.13.02.020--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.001--
Sensory loss17.02.07.007--Not Available
Shock24.06.02.002--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Suicidal ideation19.12.01.003--
Sweat discolouration23.02.03.009--Not Available
Syncope17.02.04.008; 02.01.02.008; 24.06.02.012--
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages